NASDAQ:ATEC - Alphatec Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.81 +0.04 (+1.44 %)
(As of 11/20/2018 04:00 PM ET)
Previous Close$2.77
Today's Range$2.63 - $2.87
52-Week Range$2.31 - $4.21
Volume63,800 shs
Average Volume109,295 shs
Market Capitalization$122.72 million
P/E Ratio-7.81
Dividend YieldN/A
Beta1.35
Alphatec Holdings, Inc., a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures. The company offers MIS products consisting of Battalion Lateral Spacer System and Squadron Lateral Retractor, Illico Minimally Invasive Surgery System, and BridgePoint Spinous Process Fixation System; and fixation products, such as Arsenal Screw System and Zodiac Spinal Fixation Systems. It also provides cervical and cervico-thoracic products, including Trestle Luxe Anterior Cervical Plate System, and Solanas Posterior Cervico/Thoracic Fixation System and Avalon Occipital Plate; and interbody Systems, such as Battalion Universal Spacer System, Novel PEEK and Titanium Spinal Spacers, and Alphatec Solus Locking ALIF Spinal Spacer. In addition, the company offers biologics consisting of AlphaGraft Structural Allograft Spacers, AlphaGraft ProFuse Demineralized Bone Scaffold, Amnioshield Amniotic Tissue Barrier, Alphagraft Demineralized Bone Matrix, and Neocore Osteoconductive Matrix. It sells its products through a network of independent distributors and direct sales representatives in the United States. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Receive ATEC News and Ratings via Email

Sign-up to receive the latest news and ratings for ATEC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ATEC
Previous Symbol
CUSIP02081G10
Phone760-431-9286

Debt

Debt-to-Equity Ratio1.42
Current Ratio2.36
Quick Ratio1.48

Price-To-Earnings

Trailing P/E Ratio-7.81
Forward P/E Ratio-4.19
P/E GrowthN/A

Sales & Book Value

Annual Sales$101.74 million
Price / Sales1.19
Cash Flow$0.1465 per share
Price / Cash19.18
Book Value($1.34) per share
Price / Book-2.10

Profitability

EPS (Most Recent Fiscal Year)($0.36)
Net Income$-2,290,000.00
Net Margins-10.03%
Return on Equity-78.46%
Return on Assets-9.33%

Miscellaneous

Employees138
Outstanding Shares43,210,000
Market Cap$122.72 million
OptionableNot Optionable

Alphatec (NASDAQ:ATEC) Frequently Asked Questions

What is Alphatec's stock symbol?

Alphatec trades on the NASDAQ under the ticker symbol "ATEC."

How were Alphatec's earnings last quarter?

Alphatec Holdings Inc (NASDAQ:ATEC) announced its quarterly earnings data on Thursday, November, 8th. The medical technology company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.09. The medical technology company had revenue of $23 million for the quarter, compared to analyst estimates of $23.92 million. Alphatec had a negative net margin of 10.03% and a negative return on equity of 78.46%. View Alphatec's Earnings History.

When is Alphatec's next earnings date?

Alphatec is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Alphatec.

What price target have analysts set for ATEC?

1 analysts have issued twelve-month target prices for Alphatec's stock. Their predictions range from $4.00 to $4.00. On average, they expect Alphatec's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 42.3% from the stock's current price. View Analyst Price Targets for Alphatec.

What is the consensus analysts' recommendation for Alphatec?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alphatec in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alphatec.

What are Wall Street analysts saying about Alphatec stock?

Here are some recent quotes from research analysts about Alphatec stock:
  • 1. According to Zacks Investment Research, "Alphatec Holdings, Inc. is a medical technology company focused on the design, development, manufacturing and marketing of products for the surgical treatment of spine disorders. The Company's principal product offering includes a variety of spinal implant products and systems consisted of components, such as spine screws and rods, spinal spacers, plates, and various biologics offerings. Alphatec Holdings, Inc. is headquartered in Carlsbad, California. " (11/15/2018)
  • 2. HC Wainwright analysts commented, "We have updated our model to reflect the reported financials and management guidance. For 2018, we project total revenues of $93.4M and a net loss of $0.67 per share. Alpha launches of products expected to continue. Alphatec is on track to deliver 12 alpha launches of spinal implant products in 2018. In September, the company filed 510(K) with the FDA for OsseoScrew system, which has been successfully used in thousands of procedures internationally. According to the management, its approval is expected by YE2018 with its alpha and full launches likely to follow in 1H19 and 2H19, respectively. Being the-first-of-its-kind in the US, OsseoScrew is likely to help reshape the domestic posterior fixation market. The company is also preparing an alpha launch of a comprehensive thoracolumbar fixation system in November 2018, followed by 8 to 10 alpha launches each year in 2019 and beyond." (11/12/2018)

Has Alphatec been receiving favorable news coverage?

Press coverage about ATEC stock has trended somewhat positive recently, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Alphatec earned a news impact score of 1.9 on InfoTrie's scale. They also gave media coverage about the medical technology company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an effect on the stock's share price in the near term.

Who are some of Alphatec's key competitors?

Who are Alphatec's key executives?

Alphatec's management team includes the folowing people:
  • Mr. Patrick S. Miles, Exec. Chairman & CEO (Age 52)
  • Mr. Terry M. Rich, Pres, COO & Director (Age 50)
  • Mr. Craig E. Hunsaker, Exec. VP of People & Culture, Corp. Sec. and Gen. Counsel (Age 54)
  • Mr. Jeffrey P. Rydin, Director (Age 51)
  • Mr. Jeffrey G. Black, Exec. VP & CFO (Age 49)

Who are Alphatec's major shareholders?

Alphatec's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (1.77%), Renaissance Technologies LLC (1.38%), Chubb Ltd (0.52%), PNC Financial Services Group Inc. (0.38%), Dimensional Fund Advisors LP (0.21%) and JPMorgan Chase & Co. (0.12%). Company insiders that own Alphatec stock include Brian Snider, Jeffrey G Black, John Foster, Leslie H Cross and Terry Rich. View Institutional Ownership Trends for Alphatec.

Which major investors are selling Alphatec stock?

ATEC stock was sold by a variety of institutional investors in the last quarter, including Chubb Ltd, Stonepine Capital Management LLC and Acadian Asset Management LLC. View Insider Buying and Selling for Alphatec.

Which major investors are buying Alphatec stock?

ATEC stock was acquired by a variety of institutional investors in the last quarter, including PNC Financial Services Group Inc., Renaissance Technologies LLC, Dimensional Fund Advisors LP, JPMorgan Chase & Co. and JPMorgan Chase & Co.. Company insiders that have bought Alphatec stock in the last two years include Brian Snider, Jeffrey G Black, Leslie H Cross and Terry Rich. View Insider Buying and Selling for Alphatec.

How do I buy shares of Alphatec?

Shares of ATEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alphatec's stock price today?

One share of ATEC stock can currently be purchased for approximately $2.81.

How big of a company is Alphatec?

Alphatec has a market capitalization of $122.72 million and generates $101.74 million in revenue each year. The medical technology company earns $-2,290,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Alphatec employs 138 workers across the globe.

What is Alphatec's official website?

The official website for Alphatec is http://www.alphatecspine.com.

How can I contact Alphatec?

Alphatec's mailing address is 5818 EL CAMINO REAL, CARLSBAD CA, 92008. The medical technology company can be reached via phone at 760-431-9286 or via email at [email protected]


MarketBeat Community Rating for Alphatec (NASDAQ ATEC)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  169 (Vote Outperform)
Underperform Votes:  171 (Vote Underperform)
Total Votes:  340
MarketBeat's community ratings are surveys of what our community members think about Alphatec and other stocks. Vote "Outperform" if you believe ATEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATEC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel